Ascendis Pharma Balance Sheet Health
Financial Health criteria checks 2/6
Ascendis Pharma has a total shareholder equity of €488.0M and total debt of €746.2M, which brings its debt-to-equity ratio to 152.9%. Its total assets and total liabilities are €2.0B and €1.5B respectively.
Key information
152.92%
Debt to equity ratio
€746.23m
Debt
| Interest coverage ratio | n/a |
| Cash | €572.82m |
| Equity | €487.97m |
| Total liabilities | €1.52b |
| Total assets | €2.00b |
Recent financial health updates
Recent updates
Ascendis Pharma: Rare Endocrine Compounder Entering Growth Phase (Initiating Buy)
Summary Ascendis Pharma is initiated with a buy rating, reflecting its transition to a durable, commercial-stage rare endocrine franchise. ASND's valuation premium is justified by high-quality revenue growth, multiple product launches, operating leverage, and reduced financing risk. Yorvipath and Yuviwel are driving robust pipeline momentum, with Yorvipath scaling rapidly in chronic hypoparathyroidism and Yuviwel poised for expansion in achondroplasia. The next 12–18 months are catalyst-rich, with regulatory, clinical, and commercial milestones supporting the self-funded growth strategy and platform expansion. Read the full article on Seeking AlphaStatutory Earnings May Not Be The Best Way To Understand Ascendis Pharma's (NASDAQ:ASND) True Position
We didn't see Ascendis Pharma A/S' ( NASDAQ:ASND ) stock surge when it reported robust earnings recently. We think that...
Long Term TransCon Pipeline Execution Will Shape Future Cash Flows And Business Durability
Catalysts About Ascendis Pharma Ascendis Pharma focuses on developing and commercializing long-acting therapies for rare endocrine and growth disorders using its TransCon technology platform. What are the underlying business or industry changes driving this perspective?
Long Acting TransCon Therapies Will Reshape Rare Endocrine Treatment Over The Coming Years
Catalysts About Ascendis Pharma Ascendis Pharma focuses on developing and commercializing long acting therapies for rare endocrine and growth disorders using its TransCon technology platform. What are the underlying business or industry changes driving this perspective?Financial Position Analysis
Short Term Liabilities: ASND's short term assets (€1.1B) do not cover its short term liabilities (€1.1B).
Long Term Liabilities: ASND's short term assets (€1.1B) exceed its long term liabilities (€388.5M).
Debt to Equity History and Analysis
Debt Level: ASND's net debt to equity ratio (35.5%) is considered satisfactory.
Reducing Debt: ASND's debt to equity ratio has increased from 0% to 152.9% over the past 5 years.
Debt Coverage: ASND's debt is not well covered by operating cash flow (8.1%).
Interest Coverage: Insufficient data to determine if ASND's interest payments on its debt are well covered by EBIT.
Balance Sheet
Discover healthy companies
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2026/05/31 02:33 |
| End of Day Share Price | 2026/05/29 00:00 |
| Earnings | 2026/03/31 |
| Annual Earnings | 2025/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Ascendis Pharma A/S is covered by 31 analysts. 15 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Eliana Merle | Barclays |
| Tazeen Ahmad | BofA Global Research |
| Michelle Gilson | Canaccord Genuity |